Pfizer, as part of its strategy to improve growth, plans to reorganize its business units in an effort to better coordinate drug development and commercialization. These changes are part of chief executive officer Jeffrey Kindler’s plan to “establish smaller operating units that can enhance innovation and accountability, but will draw upon the advantages of scale and resources Pfizer offers,” said Raymond Kerins, a spokesman for Pfizer. The changes will take effect in January. ...